Why 'Diabetes Insipidus' Was Renamed Arginine Vasopressin Deficiency (AVP-D)

A name is usually the least interesting thing about a disease. Arginine vasopressin deficiency is the exception. In 2022 a multi-society working group recommended retiring the centuries-old term "diabetes insipidus" and replacing it with two labels that describe the actual defect: arginine vasopressin deficiency (AVP-D) when the pituitary makes too little of the water-retaining hormone, and arginine vasopressin resistance (AVP-R) when the kidneys cannot respond to it. The recommendation was published across several endocrine journals and endorsed by most major professional societies, and its central justification was not tidiness. It was that the old name has been getting people hurt.

Key points#

• "Diabetes insipidus" was renamed in 2022 to arginine vasopressin deficiency (AVP-D, central form) and arginine vasopressin resistance (AVP-R, nephrogenic form).
• The disease and its physiology did not change; only the terminology did.
• The driver was patient safety: the shared word "diabetes" caused clinicians to confuse the condition with diabetes mellitus and, at times, to withhold desmopressin.
• Patient survey data and a national safety alert documented real harm, including deaths, from missed doses.
• Adoption is uneven because coding systems, records, and textbooks change slowly; a transitional dual format keeps the old term in parentheses.

The safety problem came first#

Most terminology debates are academic. This one started at the bedside. The word "diabetes" in "diabetes insipidus" points a busy clinician toward the far more common diabetes mellitus, a metabolic disease of blood sugar that shares essentially no biology with the water-balance disorder in question. When someone with central AVP-D is admitted to hospital, that single word can reroute their care. Staff may assume the "diabetes" on the chart refers to blood sugar, may not recognize that the patient depends on scheduled desmopressin to hold onto water, and may let a dose lapse. In this disorder a missed dose is not a minor deviation. Without desmopressin the kidneys pour out dilute urine, and dangerous dehydration can develop within hours.

The scale of that confusion was measured before the rename, not asserted after it. A patient-perspective survey of 1,034 people living with central diabetes insipidus, published in The Lancet Diabetes and Endocrinology in 2022, reported that roughly 80 percent had encountered a situation in which a health professional confused their condition with diabetes mellitus, and about 85 percent favored a name change. That finding did not stand alone. In 2016 NHS England had already issued a patient safety alert warning that omitting or delaying desmopressin in people with cranial diabetes insipidus could cause severe harm or death, citing dosing errors and cases in which a missed dose led to fatal dehydration. A large majority of patients describing the same recurring error, plus a national body documenting deaths from it, is what turned a linguistic preference into a safety argument.

That is the appraisable core of the proposal, and it is worth stating precisely. No one claims a new name treats anyone. The claim is narrower and testable: a clearer name should reduce a specific, recurring, sometimes lethal error in human communication. The survey evidence points in that direction, even though no trial has yet shown that the rename itself lowers mortality. Read as a human-factors intervention rather than a medical one, the logic holds together.

Where the old name came from#

The label is a historical fossil. "Diabetes" derives from a Greek word for a siphon, a nod to heavy urine output, and "insipidus" means tasteless, which distinguished the dilute urine of this condition from the sweet urine of "diabetes mellitus." The two diseases ended up sharing a first name because eighteenth-century physicians who diagnosed by tasting urine grouped anything that produced copious urination under "diabetes." That made sense in an era of bedside chemistry by tongue. It has made progressively less sense with every decade since, as the actual mechanisms came into focus and turned out to have almost nothing in common.

Two names, two mechanisms#

The strength of the replacement is that it points at the defect rather than the symptom. The working group, whose contributors included endocrinologists such as Mirjam Christ-Crain and Joseph Verbalis, argued that a modern disease name should name its cause.

• AVP-D (arginine vasopressin deficiency) is the central or cranial form. The problem sits in the brain: the posterior pituitary secretes too little arginine vasopressin, the antidiuretic hormone that tells the kidney to conserve water. The name states the missing ingredient.
• AVP-R (arginine vasopressin resistance) is the nephrogenic form. Here the hormone is present, but the kidney cannot respond to it. The name states the block.

The single old term blurred a pituitary problem and a kidney problem into one label, which is exactly the kind of ambiguity that invites the wrong mental model. The new pair separates them cleanly and, as a bonus, avoids eponyms in favor of plain mechanism.

Broad agreement, slow rollout#

Endorsement was wide. Backers included the Endocrine Society, the European Society of Endocrinology, the Pituitary Society, the Society for Endocrinology, the European Society for Paediatric Endocrinology, the Endocrine Society of Australia, the Brazilian Society of Endocrinology and Metabolism, and the Japan Endocrine Society. Agreement on that scale is unusual for a naming question.

Agreement, though, is not the same as adoption. Terminology is embedded in code sets, electronic health records, laboratory menus, insurance forms, and textbooks, and those systems turn over on their own slow schedule. The working group submitted a request to update the WHO's ICD-11 classification and, in the meantime, recommended a transitional dual format: "AVP deficiency (cranial diabetes insipidus)" and "AVP resistance (nephrogenic diabetes insipidus)," retaining the legacy term in parentheses so a reader who knows only the old name is not stranded. The tradeoff is honest. Dropping the old word outright would maximize the safety benefit but risks a stretch where records, clinicians, and patients speak different vocabularies for one disease. Carrying both terms preserves continuity while diluting some of the clarity the change was meant to deliver. Until ICD-11 and the systems downstream of it fully absorb AVP-D and AVP-R, patients will keep seeing the older name on their paperwork.

What it means if you carry the diagnosis#

If your records read diabetes insipidus, AVP-D, or AVP-R, they can all describe the same condition, and nothing about your physiology changed in 2022. The value of the newer terms is communication. Being able to tell an unfamiliar clinician "I have arginine vasopressin deficiency, not diabetes, and a missed desmopressin dose is an emergency" targets the exact confusion the rename was built to prevent. Whether the field settles on the new labels quickly or slowly, the durable lesson is that names are part of how medicine transmits information, and when a name misfires in a way that costs lives, correcting it is worth the effort.